[ad_1]
Thomas Mertens said in an interview with the Rheinische Post that Sputnik V “is a good vaccine that will probably be licensed in the EU one day.”
He added that Russian researchers have a lot of experience in vaccine development and that their preparation against SARS-CoV-2 is a “cleverly constructed” agent.
He explained that the development of the Gamaleja research institute belongs to a group of so-called vector vaccines, as well as a vaccine developed in collaboration with the University of Oxford and the British-Swedish pharmaceutical giant AstraZeneca. However, unlike the AstraZeneca vaccine, Sputnik V contains different viruses of the so-called vectors in the first and second doses, which is “a very smart solution because it avoids any loss of efficacy that may result from immune responses to the vectors” .
The head of the independent health policy advisory board said, among other things, that it is certain that children will also be vaccinated against SARS-CoV-2. Manufacturers are already looking at how their serums work in children, he said, noting that “it may not be some of this later this year,” but it may be possible to start vaccinating children later in the year.
When asked about the evolution of the vaccination campaign in Germany, he said that he was reluctant to give a forecast of when the vaccine could be given to whoever it wanted. At the same time, “at least I hope the effects of the vaccines will be clearly visible by the fall,” said Thomas Mertens.
He noted that the number of serious illnesses and deaths has already dropped significantly in the groups that top the campaign’s priorities, among residents of nursing homes and nursing homes.
Cover Image: Mustafa Hassona / Anadolu Agency via Getty Images
[ad_2]
